Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Insmed (INSM +6.65%) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Insmed and see what CAPS investors are saying about the stock right now.
Insmed facts
|
Headquarters (founded) |
Monmouth Junction, N.J. (1999) |
|
Market Cap |
$347.2 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month EBITDA |
($46.0 million) |
|
Management |
CEO William Lewis (since 2012) |
|
Return on Equity (average, past 3 years) |
29.2% |
|
Cash/Debt |
$81.6 million / $19.5 million |
|
Competitors |
Forest Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 18% of the 28 All-Star members who have rated Insmed believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those Fools, All-Star zzlangerhans, touched on the stock's seemingly unsustainable valuation:
I see the market cap over [$300M] excessive given the unresolved carcinogenicity concerns, the weak results of CLEAR-108 which met the primary endpoint in name only, and the questionable commercial prospects of an antibiotic for non-tuberculous mycobacterial infection even if the results of TARGET-NTM and a future phase III trial are positive.
